FDA Approves Tryvio for the Treatment of Hypertension in Combination With Other Antihypertensive Drugs to Lower Blood Pressure
In March 2024, the FDA approved aprocitentan (Tryvio), an endothelin receptor antagonist, for the treatment of hypertension in combination with other antihypertensive medications. The approval is specifically for lowering blood pressure in adult patients in which it is not adequately controlled by other medications. Aprocitentan significantly reduced sitting systolic blood pressure by 3.8 mmHg more … Read more